AI-Based Drug Discovery of TKIs Targeting L858R/T790M/C797S-Mutant EGFR in Non-small Cell Lung Cancer

Overview

Journal Front Pharmacol

Date 2021 Aug 16

PMID 34393769

Citations 5

Authors

Geunho Choi

Daegeun Kim

Junehwan Oh

Affiliations

Soon will be listed here.

Abstract

Lung cancer has a high mortality rate, and non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Patients have been observed to acquire resistance against various anticancer agents used for NSCLC due to L858R (or Exon del19)/T790M/C797S-EGFR mutations. Therefore, next-generation drugs are being developed to overcome this problem of acquired resistance. The goal of this study was to use artificial intelligence (AI) to discover drug candidates that can overcome acquired resistance and reduce the limitations of the current drug discovery process, such as high costs and long durations of drug design and production. To generate ligands using AI, we collected data related to tyrosine kinase inhibitors (TKIs) from accessible libraries and used LSTM (Long short term memory) based transfer learning (TL) model. Through the simplified molecular-input line-entry system (SMILES) datasets of the generated ligands, we obtained drug-like ligands via parameter-filtering, cyclic skeleton (CSK) analysis, and virtual screening utilizing deep-learning method. Based on the results of this study, we are developing prospective EGFR TKIs for NSCLC that have overcome the limitations of existing third-generation drugs.

Citing Articles

A Thorough Review of the Clinical Applications of Artificial Intelligence in Lung Cancer.

Kotoulas S, Spyratos D, Porpodis K, Domvri K, Boutou A, Kaimakamis E Cancers (Basel). 2025; 17(5).

PMID: 40075729 PMC: 11898928. DOI: 10.3390/cancers17050882.

Computational design of CDK1 inhibitors with enhanced target affinity and drug-likeness using deep-learning framework.

Lu Z, Han J, Ji Y, Li B, Zhang A Heliyon. 2025; 10(22):e40345.

PMID: 39748968 PMC: 11693894. DOI: 10.1016/j.heliyon.2024.e40345.

Fused in silico and bioactivity evaluation method for drug discovery: T001-10027877 was identified as an antiproliferative agent that targets EGFR and EGFR.

Wang L, Huang X, Xu S, An Y, Lv X, Zhu W BMC Chem. 2024; 18(1):159.

PMID: 39192294 PMC: 11351453. DOI: 10.1186/s13065-024-01279-z.

The role of angiogenesis in melanoma: Clinical treatments and future expectations.

Wu Z, Bian Y, Chu T, Wang Y, Man S, Song Y Front Pharmacol. 2023; 13:1028647.

PMID: 36588679 PMC: 9797529. DOI: 10.3389/fphar.2022.1028647.

Investigating the Retained Inhibitory Effect of Cobimetinib against p.P124L Mutated MEK1: A Combined Liquid Biopsy and in Silico Approach.

Catoni C, Poggiana C, Facchinetti A, Pigozzo J, Piccin L, Chiarion-Sileni V Cancers (Basel). 2022; 14(17).

PMID: 36077693 PMC: 9454486. DOI: 10.3390/cancers14174153.

References

Cai C, Wang S, Xu Y, Zhang W, Tang K, Ouyang Q . Transfer Learning for Drug Discovery. J Med Chem. 2020; 63(16):8683-8694. DOI: 10.1021/acs.jmedchem.9b02147. View

LeCun Y, Bengio Y, Hinton G . Deep learning. Nature. 2015; 521(7553):436-44. DOI: 10.1038/nature14539. View

Mak K, Pichika M . Artificial intelligence in drug development: present status and future prospects. Drug Discov Today. 2018; 24(3):773-780. DOI: 10.1016/j.drudis.2018.11.014. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Yuan M, Huang L, Chen J, Wu J, Xu Q . The emerging treatment landscape of targeted therapy in non-small-cell lung cancer. Signal Transduct Target Ther. 2019; 4:61. PMC: 6914774. DOI: 10.1038/s41392-019-0099-9. View

Li X, Xu Y, Yao H, Lin K . Chemical space exploration based on recurrent neural networks: applications in discovering kinase inhibitors. J Cheminform. 2021; 12(1):42. PMC: 7278228. DOI: 10.1186/s13321-020-00446-3. View

Cereto-Massague A, Ojeda M, Valls C, Mulero M, Garcia-Vallve S, Pujadas G . Molecular fingerprint similarity search in virtual screening. Methods. 2014; 71:58-63. DOI: 10.1016/j.ymeth.2014.08.005. View

Liu Q, Yu S, Zhao W, Qin S, Chu Q, Wu K . EGFR-TKIs resistance via EGFR-independent signaling pathways. Mol Cancer. 2018; 17(1):53. PMC: 5817859. DOI: 10.1186/s12943-018-0793-1. View

Ghosh A, Samanta I, Mondal A, Liu W . Covalent Inhibition in Drug Discovery. ChemMedChem. 2019; 14(9):889-906. PMC: 6816337. DOI: 10.1002/cmdc.201900107. View

10.

Gaulton A, Bellis L, Bento A, Chambers J, Davies M, Hersey A . ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res. 2011; 40(Database issue):D1100-7. PMC: 3245175. DOI: 10.1093/nar/gkr777. View

11.

Gupta A, Muller A, Huisman B, Fuchs J, Schneider P, Schneider G . Generative Recurrent Networks for De Novo Drug Design. Mol Inform. 2017; 37(1-2). PMC: 5836943. DOI: 10.1002/minf.201700111. View

12.

Li Q, Zhang T, Li S, Tong L, Li J, Su Z . Discovery of Potent and Noncovalent Reversible EGFR Kinase Inhibitors of EGFR. ACS Med Chem Lett. 2019; 10(6):869-873. PMC: 6580378. DOI: 10.1021/acsmedchemlett.8b00564. View

13.

Klaeger S, Heinzlmeir S, Wilhelm M, Polzer H, Vick B, Koenig P . The target landscape of clinical kinase drugs. Science. 2017; 358(6367). PMC: 6542668. DOI: 10.1126/science.aan4368. View

14.

Schuhmacher A, Gassmann O, Hinder M . Changing R&D models in research-based pharmaceutical companies. J Transl Med. 2016; 14(1):105. PMC: 4847363. DOI: 10.1186/s12967-016-0838-4. View

15.

Ozturk H, Ozgur A, Ozkirimli E . DeepDTA: deep drug-target binding affinity prediction. Bioinformatics. 2018; 34(17):i821-i829. PMC: 6129291. DOI: 10.1093/bioinformatics/bty593. View

16.

Zhai X, Ward R, Doig P, Argyrou A . Insight into the Therapeutic Selectivity of the Irreversible EGFR Tyrosine Kinase Inhibitor Osimertinib through Enzyme Kinetic Studies. Biochemistry. 2020; 59(14):1428-1441. DOI: 10.1021/acs.biochem.0c00104. View

17.

Chan H, Shan H, Dahoun T, Vogel H, Yuan S . Advancing Drug Discovery via Artificial Intelligence. Trends Pharmacol Sci. 2019; 40(8):592-604. DOI: 10.1016/j.tips.2019.06.004. View

18.

Jett J, Carr L . Targeted therapy for non-small cell lung cancer. Am J Respir Crit Care Med. 2013; 188(8):907-12. DOI: 10.1164/rccm.201301-0189PP. View

19.

Scannell J, Blanckley A, Boldon H, Warrington B . Diagnosing the decline in pharmaceutical R&D efficiency. Nat Rev Drug Discov. 2012; 11(3):191-200. DOI: 10.1038/nrd3681. View

20.

Siegel R, Miller K, Fuchs H, Jemal A . Cancer Statistics, 2021. CA Cancer J Clin. 2021; 71(1):7-33. DOI: 10.3322/caac.21654. View